Although the news was hardly a surprise, shares in Arpida AG still dropped by more than 4 percent Tuesday, following confirmation from the FDA that it would require additional clinical data to approve the Swiss firm's antibiotic iclaprim. (BioWorld Today)

The team behind two recent successful start-ups, U3 Pharma AG and NeurImmune Therapeutics AG, is applying the lessons learned from those ventures to a new investment fund and has already completed its first deal, a CHF10 million (US$8.9 million) Series A round in start-up firm CT Atlantic AG. (BioWorld International)